What GSK PLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1131399 · Filed Nov 5, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 8.6M |
| ±0% |
| $95.6M |
| 19.2% |
WVEWave Life Sciences, Inc. | 18.2M | New | $67.5M | 13.6% |
BNTXBioNTech SE | 668.5K | −24.9% | $65.7M | 13.2% |
IDYAIDEAYA Biosciences, Inc. | 1.3M | ±0% | $51.2M | 10.3% |
CYTKCytokinetics Inc | 340.4K | ±0% | $22.4M | 4.5% |
LYELLyell Immunopharma, Inc. | 1.5M | ±0% | $14.8M | 3% |
SPROSpero Therapeutics, Inc. | 9.2M | ±0% | $11.1M | 2.2% |
NKTXNkarta, Inc. | 3.2M | ±0% | $8.3M | 1.7% |
FULCFulcrum Therapeutics, Inc. | 1.8M | ±0% | $6.6M | 1.3% |
BCYCBicycle Therapeutics PLC | 1.5M | ±0% | $5.6M | 1.1% |
RGNXRegenxbio Inc. | 271.5K | ±0% | $2M | 0.4% |
CVRXCVRx, Inc. | 1M | ±0% | $1.8M | 0.4% |